The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases

Fabio Salvatore Macaluso; Sara Renna; Walter Fries; Anna Viola; Maria Cappello; Ivan Alberto Salerno; Filippo Mocciaro; Barbara Scrivo; Emiliano Giangreco; Concetta Ferracane; Maria Giovanna Minissale; Maria Emanuela Distefano; Vincenza Tortorella; Alessandro Termini; Luca Bertoncello; Ambrogio Orlando

doi:10.1093/ibd/izae248

The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases

Inflamm Bowel Dis. 2024 Oct 26:izae248. doi: 10.1093/ibd/izae248. Online ahead of print.

Authors

Fabio Salvatore Macaluso¹, Sara Renna¹, Walter Fries², Anna Viola², Maria Cappello³, Ivan Alberto Salerno³, Filippo Mocciaro⁴, Barbara Scrivo⁴, Emiliano Giangreco⁵, Concetta Ferracane⁶, Maria Giovanna Minissale⁷, Maria Emanuela Distefano⁸, Vincenza Tortorella⁹, Alessandro Termini¹, Luca Bertoncello¹, Ambrogio Orlando¹

Affiliations

¹ Inflammatory bowel disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
² Inflammatory bowel disease Unit, "G. Martino" Hospital, Messina, Italy.
³ Gastroenterology and Hepatology Section, PROMISE, University of Palermo, Palermo, Italy.
⁴ Gastroenterology and Endoscopy Unit, "ARNAS Civico - Di Cristina - Benfratelli" Hospital, Palermo, Italy.
⁵ Gastroenterology Unit, "Guzzardi" Hospital, Vittoria, Italy.
⁶ Gastroenterology Unit, "Vittorio Emanuele" Hospital, Catania, Italy.
⁷ Gastroenterology and Endoscopy Unit, A.O. "Buccheri La Ferla Fatebenefratelli," Palermo, Italy.
⁸ IBD Unit, "Cannizzaro" Hospital, Catania, Italy.
⁹ Gastroenterology Unit, A.O.O.R. "Papardo Piemonte," Messina, Italy.

PMID: 39460746
DOI: 10.1093/ibd/izae248

No abstract available

Keywords: biologics; clinical remission; real-world evidence.

Plain language summary

This multicentre cohort study showed that Risankizumab is an effective induction therapy in patients with Crohn’s disease, and that the best results are obtained when Risankizumab is used as second-line therapy following a previous failure with a TNF inhibitor.